The Coronary Calcium Score: What a “Zero” Really Means, and What It Can Miss
Executive summary
The coronary artery calcium (CAC) score measures calcified atherosclerotic plaque in the heart's own arteries. A computed tomography (CT) scanner grades each deposit by its area and its density and sums the result into one number, the Agatston score (Ref 1). The radiation is modest: historically an effective dose of 0.8 to 10.5 millisieverts (mSv) depending on protocol, with a median around 2.3 mSv, and modern scanners sit at the low end (Ref 2).
A score of zero is genuinely reassuring. In a systematic review of roughly 85,000 people, only 0.56% of asymptomatic individuals with a zero had a cardiovascular event over about four years (Ref 5), and a zero has been linked to a roughly fifteen-year "warranty period" of low mortality (Ref 6).
CAC predicts events across ethnic groups and adds information on top of the standard risk factors, most usefully in people at intermediate risk where the decision to treat is genuinely on the fence (Ref 3, Ref 4). Among the widely studied newer markers, calcium scoring improved prediction the most (Ref 7, Ref 8).
A zero is not a guarantee. The scan sees only calcified plaque; softer, non-calcified plaque is invisible to it and can still rupture. In a 2025 analysis, 23% of people presenting with a heart attack or unstable angina had a CAC of zero, and their arteries carried non-calcified plaque (Ref 12).
Age matters. In adults aged 32 to 46, any calcium at all carried roughly a five-fold higher risk of coronary heart disease (Ref 13), and a zero earned at 40 says less about the following decades than a zero at 65.
The score earns its keep when it changes a decision. Among people a guideline would make statin-eligible, about 44% had a calcium score of zero with a low event rate, which reclassified roughly half of them out of drug eligibility, while a high score marks those at materially higher near-term risk (Ref 10). Guidelines accordingly treat CAC as a decision aid in selected, borderline-to-intermediate-risk adults (Ref 11).
Statins muddy repeat scans: they tend to increase the calcium density of plaque even while shrinking its total volume (Ref 14), so a number that rises on treatment does not simply mean "worse."
The practical filter is a single question: would the result change what you and your clinician actually do? A CAC scan is most useful for the genuinely undecided and least useful for the very-low-risk young person, or for anyone who would be treated, or not, regardless of the number.
Introduction
A recurring claim in the online metabolic-health world is that people have driven their coronary artery calcium (CAC) score down to zero, and that a zero proves the arteries are clean. The "power of zero" is real, but it is narrower than the slogan suggests. This article sets out what a calcium score does and does not tell you, the cohort evidence behind it, and the one question I think should decide whether anyone has the scan at all.
I should declare my position. I run a private clinic (drabs.clinic) where consultations are paid, and my professional interest is in metabolic health and longevity. I am sympathetic to low-carbohydrate and metabolic approaches, and I am sceptical of treating a number rather than a person. Those leanings could bias how I read this literature, so I have tried to cite the mainstream evidence in full and then criticise it fairly. Every study below was checked against PubMed for its actual finding rather than the version I might have preferred.
What a calcium score actually measures
Coronary arteries are the small vessels that supply the heart muscle itself. Atherosclerosis, the disease process behind most heart attacks, deposits a mixture of fats, inflammatory cells and, over time, calcium into their walls. The CAC scan is a quick, contrast-free CT (computed tomography) of the chest that detects that calcium. The scoring method, described by Agatston and colleagues in 1990, multiplies the area of each calcified deposit by a factor for its peak density and adds the pieces together (Ref 1). A score of zero means no detectable calcified plaque; higher numbers mean more.
Two features of that definition matter for everything that follows. First, the scan measures calcium, which is a marker of established, healed plaque, not of the soft, early plaque that has not yet calcified. Second, the exposure is real but modest. A 2009 analysis put the effective dose between 0.8 and 10.5 millisieverts (mSv) depending on the scanner protocol, with a median around 2.3 mSv (Ref 2); contemporary prospectively gated protocols sit near the bottom of that range, comparable to a few months of natural background radiation. Neither the cost nor the radiation is large, but neither is quite zero, and that matters when we come to who should be scanned.
The power of zero: the evidence a zero is reassuring
The strongest thing that can be said for calcium scoring is what a zero predicts. A 2009 systematic review pooling 49 studies and more than 85,000 people found that, among asymptomatic individuals with a CAC of zero, just 0.56% had a cardiovascular event over a mean of about four years (Ref 5). A later prospective follow-up of 9,715 people reported that a baseline zero was associated with low mortality, under roughly 1% per year, for around fifteen years, which is where the phrase "warranty period" comes from (Ref 6). And in the Multi-Ethnic Study of Atherosclerosis (MESA), a population sample of 6,722 adults, calcium predicted coronary events in white, black, Hispanic and Chinese participants alike; compared with no calcium, a score above 300 carried close to a ten-fold higher adjusted risk (a hazard ratio of 9.67) (Ref 3).
Cite, then critique. These are observational cohorts, not trials, so they show association, not proof that the scan itself improves outcomes. The people who get scanned are a selected group, often the risk-aware and comparatively healthy, which can flatter a zero. Most importantly, a zero means no calcified plaque, not no atherosclerosis. It is a statement about a roughly fifteen-year horizon of low risk in populations, not a personal guarantee, and the warranty is shorter in younger people whose disease has had less time to calcify.
What CAC adds beyond the usual risk factors
Standard risk calculators use age, sex, blood pressure, smoking, diabetes and a lipid panel. The interesting question is whether a calcium scan adds anything to those. In an early prospective study of 1,312 asymptomatic adults, calcium refined risk among people whose Framingham risk was above 10% but not among those below 10%; in other words, it helped precisely in the intermediate band where the decision to treat is least clear (Ref 4). In MESA, adding the calcium score reclassified a meaningful share of people into more accurate risk categories, with a net reclassification improvement of 0.25 (Ref 7). When several fashionable markers were compared head to head in intermediate-risk adults, including C-reactive protein, ankle-brachial index and family history, the calcium score was the strongest and improved reclassification the most (Ref 8). Researchers have since folded CAC into a risk equation that lifts the model's discrimination, or C-statistic, from 0.75 to 0.80 (Ref 9).
The caveats are familiar. All of this is observational, and much of it comes from the same cohort, so the findings travel together and could share the same blind spots. Reclassification statistics reward a test for moving people between arbitrary risk bands and do not, by themselves, show that acting on the new category makes anyone live longer. What the data support is narrower but still useful: in the right person, the score sharpens an uncertain estimate.
Where a zero can mislead
Because the scan sees only calcium, it can miss the plaque that most often kills. Soft, non-calcified plaque can rupture and cause a heart attack while the calcium score reads zero. A 2025 case-control analysis nested in the CONFIRM registry looked at people who had presented with an acute coronary syndrome, meaning a heart attack or unstable angina, and found that 23% of them had a CAC of zero; when their arteries were imaged with CT angiography, the culprit lesions were made of non-calcified fibrous, fibrofatty and necrotic-core plaque that the calcium score never registered (Ref 12). That is the clearest illustration of the limit: a zero lowers the odds, it does not abolish them, and in someone with symptoms it can be falsely reassuring.
Age sharpens the point in the other direction. In adults aged 32 to 46 in the CARDIA study, finding any calcium at all was a strong signal, carrying roughly a five-fold higher risk of coronary heart disease (Ref 13). So a young person with a positive score has a genuinely concerning finding, while a young person with a zero has bought less time than an older person with a zero, because calcification simply takes years to appear.
The statin wrinkle, and the reversal stories
Two things are worth separating here, because the popular narrative tends to fuse them. The first is what statins do to the calcium score. A pooled analysis of eight trials that tracked plaque with intravascular ultrasound found that intensive statin therapy shrank the total volume of plaque yet increased its calcium content in every group studied (Ref 14). The usual interpretation is that the drugs push plaque toward a denser, more stable, more calcified form, though that reading is inferred rather than proven. The practical consequence is concrete: a calcium score can rise on a statin without the underlying disease getting worse, so serial scans in someone on treatment are hard to interpret, and chasing the number is a poor idea.
The second is the online genre of dramatic reversals, including reports of a near-complete blockage said to have cleared on a low-carbohydrate, animal-based diet. It is worth being honest about what such a story can and cannot establish. If an initial CT angiogram showed a stenosis made largely of soft, non-calcified plaque, then a later scan showing improvement is a statement about that soft plaque, not about the calcium score, and it is biologically plausible that non-calcified plaque can regress. Calcified plaque, by contrast, rarely disappears. Either way, a single self-reported case, with no verified baseline, no control group and a diet recalled from memory, is a hypothesis, not evidence. The same limitation applies to the reassuring cases: people who report a zero after years of a particular way of eating may well be telling the truth, but selection and recall make it impossible to attribute the outcome to the diet with confidence.
There is, however, a legitimate observation buried in these anecdotes. Lipid levels and calcium scores do not always agree. In the statin-eligibility analysis discussed in the next section, a substantial minority of people with a high enough LDL (low-density lipoprotein) or ApoB (apolipoprotein B) to qualify for medication, and these are the cholesterol-carrying lipoproteins rather than cholesterol itself, nonetheless had a calcium score of zero and a low near-term event rate (Ref 10). That discordance is real and clinically useful. It does not, on its own, prove that a high LDL or ApoB is harmless, and I would be overstating the evidence if I claimed it did.
What this means in practice
Put the strengths and the limits together and the calcium score stops being a slogan and becomes a tool with a job. The job is to break a genuine tie. The 2019 American College of Cardiology and American Heart Association prevention guideline reflects this, positioning CAC as a reasonable option to guide preventive treatment in selected adults, broadly those aged about 40 to 75 at borderline-to-intermediate risk in whom the decision to start a statin is uncertain (Ref 11). The supporting data are direct: in a MESA analysis of people a guideline would have made statin-eligible, about 44% had a calcium score of zero with an event rate of roughly 4.2 per 1,000 person-years, and absence of calcium reclassified around half of them as no longer clearly needing the drug, while a high score did the opposite (Ref 10).
That is exactly the situation in which I think a scan is worth doing: a person on the fence, weighing years or decades of medication, for whom a zero or a high number would genuinely change the plan. It is just as important to name who does not benefit. A very-low-risk young person gains little, because a zero was the expected result and changes nothing, while a small radiation dose, the chance of an incidental finding and the cost are real if minor downsides. A person already at high risk, who would be treated whatever the scan showed, does not need the number to make the decision. Anyone who has decided in advance to ignore an inconvenient result should save their money. And someone with actual symptoms is a different problem altogether: they need proper assessment, not a screening calcium score, precisely because a zero can miss the soft plaque behind an acute event (Ref 12).
A few practical cautions follow from the evidence rather than from opinion. Do not repeat the scan often in the hope of watching a number fall, especially on a statin, where the calcium content is expected to rise regardless (Ref 14). Do not read a zero as permission to stop attending to blood pressure, ApoB, glucose control, sleep, muscle and the other ordinary determinants of a long life. And treat the decision to start or stop any medication as a conversation with your own prescriber first; a calcium score is one input to that conversation, not a verdict, and clinicians who recommend statins are usually working faithfully within risk-score-driven guidelines rather than acting carelessly.
If it would help to think through whether a calcium score, or anything else, would actually change your plan, I offer consultations, though there are many excellent clinicians who can do the same.
Disclosures
I run a private clinic (drabs.clinic) where consultations are paid, and my professional focus is metabolic health and longevity. I am sympathetic to low-carbohydrate and metabolic approaches and sceptical of treating numbers rather than people, which may colour my reading of this evidence; readers should weigh it accordingly. I have no financial relationship with any manufacturer of CT scanners, statins or the supplements sometimes marketed alongside this topic. According to PubMed, from which every reference below was retrieved and verified, the studies are as cited, and each is linked by its DOI.
References
Agatston AS, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol, 1990;15(4):827-832. https://doi.org/10.1016/0735-1097(90)90282-t
Kim KP, Einstein AJ, Berrington de González A. Coronary artery calcification screening: estimated radiation dose and cancer risk. Arch Intern Med, 2009;169(13):1188-1194. https://doi.org/10.1001/archinternmed.2009.162
Detrano R, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med, 2008;358(13):1336-1345. https://doi.org/10.1056/NEJMoa072100
Greenland P, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA, 2004;291(2):210-215. https://doi.org/10.1001/jama.291.2.210
Sarwar A, et al. Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging, 2009;2(6):675-688. https://doi.org/10.1016/j.jcmg.2008.12.031
Valenti V, et al. A 15-year warranty period for asymptomatic individuals without coronary artery calcium: a prospective follow-up of 9,715 individuals. JACC Cardiovasc Imaging, 2015;8(8):900-909. https://doi.org/10.1016/j.jcmg.2015.01.025
Polonsky TS, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA, 2010;303(16):1610-1616. https://doi.org/10.1001/jama.2010.461
Yeboah J, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA, 2012;308(8):788-795. https://doi.org/10.1001/jama.2012.9624
McClelland RL, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA with validation in the HNR study and the DHS. J Am Coll Cardiol, 2015;66(15):1643-1653. https://doi.org/10.1016/j.jacc.2015.08.035
Nasir K, et al. Implications of coronary artery calcium testing among statin candidates according to ACC/AHA cholesterol management guidelines: MESA. J Am Coll Cardiol, 2015;66(15):1657-1668. https://doi.org/10.1016/j.jacc.2015.07.066
Arnett DK, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation, 2019;140(11):e563-e595. https://doi.org/10.1161/CIR.0000000000000677
Jonas RA, et al. CTA-derived plaque characteristics and risk of acute coronary syndrome in patients with coronary artery calcium score of zero: insights from the ICONIC trial. AJR Am J Roentgenol, 2025;225(1):e2431476. https://doi.org/10.2214/AJR.24.31476
Carr JJ, et al. Association of coronary artery calcium in adults aged 32 to 46 years with incident coronary heart disease and death. JAMA Cardiol, 2017;2(4):391-399. https://doi.org/10.1001/jamacardio.2016.5493
Puri R, et al. Impact of statins on serial coronary calcification during atheroma progression and regression. J Am Coll Cardiol, 2015;65(13):1273-1282. https://doi.org/10.1016/j.jacc.2015.01.036
